Variant report
Variant | esv3457349 |
---|---|
Chromosome Location | chr2:11081775-11082221 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:3)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
(count:3 , 50 per page) page:
1
No data |
No data |
No data |
No data |

No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs569040147 | chr2:11081816-11081817 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
2 | rs553675230 | chr2:11081841-11081842 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs572240496 | chr2:11081895-11081896 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs4669652 | chr2:11081916-11081917 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
5 | rs557853586 | chr2:11081918-11081919 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs34783361 | chr2:11081919-11081920 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs397741544 | chr2:11081929-11081930 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs375782697 | chr2:11081945-11081946 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs36027771 | chr2:11081957-11081958 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs536473340 | chr2:11081960-11081961 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs143046388 | chr2:11081968-11081969 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
12 | rs543423891 | chr2:11081992-11081993 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs553550058 | chr2:11082004-11082005 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
14 | rs562000393 | chr2:11082053-11082054 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
15 | rs184031480 | chr2:11082058-11082059 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs541741313 | chr2:11082063-11082064 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
17 | rs148218194 | chr2:11082068-11082069 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
18 | rs112208863 | chr2:11082079-11082080 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
19 | rs188757928 | chr2:11082083-11082084 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
20 | rs397872971 | chr2:11082086-11082087 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs552266596 | chr2:11082111-11082112 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs34570170 | chr2:11082112-11082113 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
23 | rs181476583 | chr2:11082115-11082116 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
24 | rs142778231 | chr2:11082125-11082126 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
25 | rs186997931 | chr2:11082159-11082160 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
26 | rs191742316 | chr2:11082185-11082186 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
27 | rs547698499 | chr2:11082190-11082191 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
28 | rs6711653 | chr2:11082191-11082192 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
29 | rs182373003 | chr2:11082193-11082194 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
30 | rs186372728 | chr2:11082195-11082196 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
31 | rs557790424 | chr2:11082205-11082206 | Weak transcription Bivalent Enhancer Enhancers | n/a | n/a | Overlapped CNVs | n/a |
32 | rs374162610 | chr2:11082207-11082208 | Weak transcription Bivalent Enhancer Enhancers | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Breast cancer | 17133270 | CNVD |
Mental retardation | 17847001 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Malignant fibrous histiocytomas | 21085701 | CNVD |
Cancer | 20164920 | CNVD |
Neuroblastoma | 21508638 | CNVD |
Breast cancer | 17603634 | CNVD |
Cancer | 16751803 | CNVD |
Neuroblastoma | 16790693 | CNVD |
Colorectal cancer | 16272173 | CNVD |
Breast cancer | 17393978 | CNVD |
Acute lymphoblastic leukemia | 21098271 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Lynch syndrome | 18415027 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Diffuse large b-cell lymphoma | 18287131 | CNVD |
Ovarian neoplasms | 16753589 | CNVD |
Glioblastoma multiforme | 17387387 | CNVD |
Neuroblastoma | 17533364 | CNVD |
Neuroblastoma | 18923191 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Adrenal tumor | 17535989 | CNVD |
Breast cancer | 21264507 | CNVD |
Basal cell lymphoma | 17053054 | CNVD |
Medulloblastoma | 17522785 | CNVD |
Cancer | 23418310 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Ependymoma | 16718352 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Lung cancer | 18438408 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Acute lymphoblastic leukemia | 18458336 | CNVD |
lymphocytic leukemia | 21291569 | CNVD |
Prostate cancer | 18632612 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Bladder cancer | 21909424 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Intellectual disability | 22102821 | CNVD |
Autism | 22495311 | CNVD |
Cancer | 20164919 | CNVD |
Hodgkin''s lymphoma | 18641027 | CNVD |
High-grade prostatic intraepithelial neoplasia | 16573809 | CNVD |
Breast cancer | 21364760 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Follicular lymphoma | 20505157 | CNVD |
Autism | 17483303 | CNVD |
Breast cancer | 21804112 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Glioblastoma multiforme | 22286061 | CNVD |
Invasive pancreatic ductal carcinoma | 16982739 | CNVD |
Glioma | 17123091 | CNVD |
Breast cancer | 20409316 | CNVD |
Multiple myeloma | 16616336 | CNVD |
Myofibroblastic sarcoma | 19369631 | CNVD |
Esophageal adenocarcinoma | 18519675 | CNVD |
Ependymoma | 18628472 | CNVD |
Leukemia | 18628472 | CNVD |
Acute myeloid leukemia | 21251322 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr2:11075800-11082800 | Weak transcription | Fetal Brain Male | brain |
2 | chr2:11076600-11087600 | Weak transcription | iPS DF 19.11 Cell Line | embryonic stem cell |
3 | chr2:11079800-11087200 | Weak transcription | A549 | lung |
4 | chr2:11080000-11081800 | Weak transcription | Breast variant Human Mammary Epithelial Cells (vHMEC) | Breast |
5 | chr2:11080000-11083600 | Enhancers | Skeletal Muscle Female | skeletal muscle |
6 | chr2:11080400-11082600 | Enhancers | Skeletal Muscle Male | skeletal muscle |
7 | chr2:11080800-11092000 | Weak transcription | ES-I3 Cell Line | embryonic stem cell |
8 | chr2:11081400-11104600 | Weak transcription | Right Atrium | heart |
9 | chr2:11081600-11081800 | Enhancers | Cortex derived primary cultured neurospheres | brain |
10 | chr2:11081600-11081800 | Bivalent Enhancer | Fetal Muscle Leg | muscle |
11 | chr2:11082200-11082400 | Bivalent Enhancer | Fetal Muscle Trunk | muscle |